Ovarian Cancer in Older Women

Seminars in Oncology

Volumn 35, Issue 6, 2008, Pages 582-589

  Tew, William P ^a   Lichtman, Stuart M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEMCITABINE; PACLITAXEL; TOPOTECAN;

ABDOMINAL HYSTERECTOMY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER RISK; CANCER SURVIVAL; HUMAN; NEUROPATHY; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE;

AGED; AGING; FEMALE; GERIATRIC ASSESSMENT; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 56249136579     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2008.08.007     Document Type: Article

References (68)

1. Edwards B.K., Howe H.L., Ries L.A., et al. Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer 94 (2002) 2766-2792
2. Yancik R., and Ries L.A. Cancer in older persons: an international issue in an aging world. Semin Oncol 31 (2004) 128-136
3. Thigpen T., Brady M.F., Omura G.A., et al. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer 71 (1993) 606-614
4. Hightower R.D., Nguyen H.N., Averette H.E., et al. National survey of ovarian carcinoma. IV: Patterns of care and related survival for older patients. Cancer 73 (1994) 377-383
5. Pignata S., and Vermorken J.B. Ovarian cancer in the elderly. Crit Rev Oncol Hematol 49 (2004) 77-86
6. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
7. Ries L.A., Melbert D., and Krapcho M. SEER cancer statistics review, 1975-2005 (2008), National Cancer Institute, Bethesda, MD
8. Watson P., Butzow R., Lynch H.T., et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 82 (2001) 223-228
9. Chen S., Iversen E.S., Friebel T., et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24 (2006) 863-871
10. Haber D. Prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in carriers of BRCA mutations. N Engl J Med 346 (2002) 1660-1662
11. Kauff N.D., Domchek S.M., Friebel T.M., et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 26 (2008) 1331-1337
12. Chi D.S., and Sabbatini P. Advanced ovarian cancer. Curr Treat Options Oncol 1 (2000) 139-146
13. Mirhashemi R., Nieves-Neira W., and Averette H.E. Gynecologic malignancies in older women. Oncology (Williston Park) 15 (2001) 580-586
14. Lambrou N.C., and Bristow R.E. Ovarian cancer in elderly women. Oncology (Williston Park) 17 (2003) 1075-1081
15. Ryerson A.B., Eheman C., Burton J., et al. Symptoms, diagnoses, and time to key diagnostic procedures among older U.S. women with ovarian cancer. Obstet Gynecol 109 (2007) 1053-1061
16. Winter III W.E., Maxwell G.L., Tian C., et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 3621-3627
17. Chan J.K., Loizzi V., Lin Y.G., et al. Stages III and IV invasive epithelial ovarian carcinoma in younger versus older women: what prognostic factors are important?. Obstet Gynecol 102 (2003) 156-161
18. Chan J.K., Urban R., Cheung M.K., et al. Ovarian cancer in younger vs older women: a population-based analysis. Br J Cancer 95 (2006) 1314-1320
19. Markman M., Lewis Jr. J.L., Saigo P., et al. Impact of age on survival of patients with ovarian cancer. Gynecol Oncol 49 (1993) 236-239
20. Petignat P., Fioretta G., Verkooijen H.M., et al. Poorer survival of elderly patients with ovarian cancer: a population-based study. Surg Oncol 13 (2004) 181-186
21. Du X.L., Sun C.C., Milam M.R., et al. Ethnic differences in socioeconomic status, diagnosis, treatment, and survival among older women with epithelial ovarian cancer. Int J Gynecol Cancer 18 (2008) 660-669
22. Pectasides D., Fountzilas G., Aravantinos G., et al. Epithelial ovarian carcinoma in younger vs older women: is age an independent prognostic factor?. The Hellenic Oncology Cooperative Group experience. Int J Gynecol Cancer 17 (2007) 1003-1010
23. Bristow R.E., Tomacruz R.S., Armstrong D.K., et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
24. Wimberger P., Lehmann N., Kimmig R., et al. Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 100 (2006) 300-307
25. Uyar D., Frasure H.E., Markman M., et al. Treatment patterns by decade of life in elderly women (> or = 70 years of age) with ovarian cancer. Gynecol Oncol 98 (2005) 403-408
26. Wright J.D., Herzog T.J., and Powell M.A. Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190 (2004) 1398-1400
27. Sharma S., Driscoll D., Odunsi K., et al. Safety and efficacy of cytoreductive surgery for epithelial ovarian cancer in elderly and high-risk surgical patients. Am J Obstet Gynecol 193 (2005) 2077-2082
28. Eisenhauer E.L., Tew W.P., Levine D.A., et al. Response and outcomes in elderly patients with stages IIIC-IV ovarian cancer receiving platinum-taxane chemotherapy. Gynecol Oncol 106 (2007) 381-387
29. Bruchim I., Altaras M., and Fishman A. Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer. Gynecol Oncol 86 (2002) 274-278
30. Nordin A.J., Chinn D.J., Moloney I., et al. Do elderly cancer patients care about cure?. Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol Oncol 81 (2001) 447-455
31. Cloven N.G., Manetta A., Berman M.L., et al. Management of ovarian cancer in patients older than 80 years of Age. Gynecol Oncol 73 (1999) 137-139
32. Susini T., Scambia G., Margariti P.A., et al. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol Oncol 75 (1999) 437-443
33. Diaz-Montes T.P., Zahurak M.L., Giuntoli II R.L., et al. Surgical care of elderly women with ovarian cancer: a population-based perspective. Gynecol Oncol 99 (2005) 352-357
34. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
35. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
36. Maas H.A., Kruitwagen R.F., Lemmens V.E., et al. The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study. Gynecol Oncol 97 (2005) 104-109
37. Hershman D., Jacobson J.S., McBride R., et al. Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer. Gynecol Oncol 94 (2004) 540-549
38. Sundararajan V., Hershman D., Grann V.R., et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 20 (2002) 173-178
39. Pignata S., and Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma. Eur J Cancer 36 (2000) 817-820
40. Pignata S., Breda E., Scambia G., et al. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study. Crit Rev Oncol Hematol 66 (2008) 229-236
41. Tredan O., Geay J.F., Touzet S., et al. Carboplatin/cyclophosphamide or carboplatin/paclitaxel in elderly patients with advanced ovarian cancer?. Analysis of two consecutive trials from the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens. Ann Oncol 18 (2007) 256-262
42. Fader A.N., Gruenigen V.V., Gibbons H., et al. Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients. Gynecol Oncol 109 (2008) 33-38
43. ICON Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360 (2002) 505-515
44. Villella J.A., Chaudhry T., Pearl M.L., et al. Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol 86 (2002) 316-322
45. Ceccaroni M., D'Agostino G., Ferrandina G., et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy?. An Italian retrospective toxicity multicentric study. Gynecol Oncol 85 (2002) 445-450
46. Alberts D.S., Liu P.Y., Hannigan E.V., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
47. Markman M., Bundy B.N., Alberts D.S., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
48. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
49. Wenzel L.B., Huang H.Q., Armstrong D.K., et al. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 25 (2007) 437-443
50. Brenner B.M., Meyer T.W., and Hostetter T.H. Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307 (1982) 652-659
51. Launay-Vacher V., Chatelut E., Lichtman S.M., et al. Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. Ann Oncol 18 (2007) 1314-1321
52. Launay-Vacher V., Oudard S., Janus N., et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency and Anticancer Medications (IRMA) study. Cancer 110 (2007) 1376-1384
53. Lichtman S.M., Wildiers H., Launay-Vacher V., et al. International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. Eur J Cancer 43 (2007) 14-34
54. Lichtman S.M., Hollis D., Miller A.A., et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 24 (2006) 1846-1851
55. Lichtman S.M., Wildiers H., Chatelut E., et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 25 (2007) 1832-1843
56. Parmar M.K., Ledermann J.A., Colombo N., et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
57. Pfisterer J., Plante M., Vergote I., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
58. Bukowski R.M., Ozols R.F., and Markman M. The management of recurrent ovarian cancer. Semin Oncol 34 (2007) S1-S15
59. Gridelli C., Langer C., Maione P., et al. Lung cancer in the elderly. J Clin Oncol 25 (2007) 1898-1907
60. Wildiers H., Kunkler I., Biganzoli L., et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8 (2007) 1101-1115
61. Gronlund B., Hogdall C., Hansen H.H., et al. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer 94 (2002) 1961-1967
62. Gordon A.N., Tonda M., Sun S., et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8
63. Morris R.T. Weekly topotecan in the management of ovarian cancer. Gynecol Oncol 90 (2003) S34-S38
64. Burger R.A. Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25 (2007) 2902-2908
65. Lewin S.N., Buttin B.M., Powell M.A., et al. Resource utilization for ovarian cancer patients at the end of life: how much is too much?. Gynecol Oncol 99 (2005) 261-266
66. Hurria A., Lichtman S.M., Gardes J., et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J Am Geriatr Soc 55 (2007) 1604-1608
67. Freyer G., Geay J.F., Touzet S., et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol 16 (2005) 1795-1800
68. Moore D.H., Kauderer J.T., Bell J., et al. An assessment of age and other factors influencing protocol versus alternative treatments for patients with epithelial ovarian cancer referred to member institutions: a Gynecologic Oncology Group study. Gynecol Oncol 94 (2004) 368-374